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ABSTRACT 43 
Background: The recent update of the Bethesda system for reporting thyroid cytology (TBSRTC) 44 
is a very important development in the evaluation of thyroid nodules. Clinical experience and 45 
scientific literature both show that practitioners performing thyroid FNA are accustomed to 46 
basing the clinical management of patients on reports using TBSRTC. Specifically, clinicians are 47 
familiar with the per cent risk of malignancy (ROM) corresponding to each TBSRTC diagnostic 48 
category (DC), as well as with the respective recommendation for clinical management. 49 
However, most clinicians are much less familiar with the specific considerations that lie 50 
between a specific DC, on the one end, and the respective ROM and associated management 51 
recommendation, on the other end. 52 
Summary: A deeper understanding of the system can enlighten the clinician’s thinking about 53 
the specific nodule under examination and can guide the decision-making process in a more 54 
meaningful way. Such an understanding can only be developed via close, two-way 55 
communication between cytopathologists and clinicians. Through this type of interaction in our 56 
tertiary medical center, we identified a set of recurring issues of particular importance for 57 
clinical practice, which we report here in the form of 16 Frequently Asked Questions (FAQ) 58 
posed by the clinician to the cytopathologist. 59 
Conclusions: For each FAQ, we provide an answer based on the literature, our experience, the 60 
new version of TBSRTC and the new World Health Organization classification of tumors of 61 
endocrine organs. 62 
 63 
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INTRODUCTION 64 
Thyroid fine-needle aspiration cytology (FNAC) is the most accurate and cost-effective 65 
tool in the initial management of patients with thyroid nodules, and its diagnostic yield can be 66 
increased when it is associated with ultrasound (US) examination and, in case of indeterminate 67 
cytological diagnosis, with molecular genetic testing. Although it is not perfect, thyroid FNA has 68 
reduced the number of surgeries performed by better distinguishing nodules that require 69 
surgery from those that do not (1-6). A major landmark was the creation of a uniform system 70 
for reporting thyroid cytopathology after a 2007 conference in Bethesda, MD, hence named 71 
͞the Bethesda system for reporting thyroid cytopathology͟ (TBSRTC) (7). TBSRTC consists of 6 72 
diagnostic categories (DCs): non-diagnostic/unsatisfactory (ND/UNS); benign (B); atypia of 73 
undetermined significance or follicular lesion of undetermined significance (AUS/FLUS); 74 
follicular neoplasm/suspicious for follicular neoplasm (FN/SFN); suspicious for malignancy (SM); 75 
and malignant (M). Each DC is associated with a specific ROM and a respective clinical 76 
management recommendation. This has contributed to making TBSRTC very popular across the 77 
world, as witnessed by the high number of publications using it (8-11). TBSRTC has also 78 
contributed to facilitating the communication between the cytopathologists and the clinicians 79 
who perform FNA or manage patients according to FNAC results. By increasing the quality and 80 
reproducibility of thyroid cytology, TBSRTC has become highly popular also in the clinical 81 
community, as shown by its endorsement by the American Thyroid Association (ATA) as part of 82 
the revised 2015 ATA guidelines for the management of thyroid nodules in adults (12).  83 
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Recently, the second edition of TBSRTC was published (13); the update was made 84 
necessary by mainly two reasons. Firstly, recent advances in the molecular diagnosis of thyroid 85 
nodules made it important to specify their place in the post-FNA management algorithm for 86 
each specific DC. Secondly, the non-invasive encapsulated follicular variant of papillary thyroid 87 
carcinoma (FV-PTC) was renamed as non-invasive follicular thyroid neoplasm with papillary-like 88 
nuclear features (NIFTP), and it was recognized by the new World Health Organization (WHO) 89 
classification of tumors of endocrine organs as a lesion whose malignant potential is much 90 
lower than that of conventional papillary thyroid carcinoma (PTC) (14).  As a consequence, the 91 
recalculated ROM ranges also needed to take into account whether NIFTP is considered as a 92 
carcinoma or not (15).  93 
The update of TBSRTC is thus a very important and welcome development. Indeed, 94 
clinical experience shows that practitioners performing thyroid FNA are accustomed to basing 95 
the clinical management of the patients on reports using TBSRTC. Specifically, clinicians are 96 
familiar with: (i) the per cent risk of malignancy associated with each TBSRTC diagnostic 97 
category, and (ii) the respective recommendation for clinical management (the options in the 98 
original version were: observe, repeat FNA or refer for surgery). However, most clinicians are 99 
much less familiar with the specific considerations and details that lie between a specific DC, on 100 
the one end, and the respective ROM and associated management recommendation, on the 101 
other end. This is unfortunate, because a deeper understanding of the system can enlighten the 102 
clinician’s thinking about the specific nodule under examination and can guide the decision-103 
making process in a more meaningful way. Such an understanding can only be developed via 104 
close, two-way communication between the cytopathologist and the clinician. Based on this 105 
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type of interaction in our thyroid clinic, as well as on an informal survey among our 106 
endocrinology colleagues dealing routinely with thyroid patients in our tertiary medical center, 107 
we identified a set of recurring issues of particular importance for clinical practice, which we 108 
report here in the form of Frequently Asked Questions (FAQ) posed by the clinician to the 109 
cytopathologist. For each FAQ, we provide an answer based on the literature, our experience, 110 
the new version of TBSRTC and the new WHO classification of tumors of endocrine organs (13, 111 
16). 112 
 113 
FAQ 1: What are the most important modifications in the updated version of TBSRTC? 114 
The most important modification in the updated version of TBSRTC concerns the ROM. 115 
First, the ROM ranges have been updated according to the most recent literature data. 116 
Moreover, for each DC, two different ROM ranges are indicated: one by considering NIFTP as 117 
carcinoma and the other by considering NIFTP as a non-malignant or pre-malignant lesion. 118 
The general schema of 6 DCs is maintained, as well as the designation of each individual 119 
DC. The updated version of TBSRTC includes some explanations that were necessary to avoid 120 
subjective interpretations possible in the previous classification. In particular, the AUS/FLUS DC 121 
should not be split, meaning that it should not be used to identify separately cases with 122 
cytological (mostly nuclear) atypia – i.e., AUS – and cases with architectural (mostly 123 
microfollicular) atypia – i.e., FLUS. The terms AUS and FLUS are to be considered synonymous 124 
and used together as AUS/FLUS. The same applies to the terms FN and SFN (FN/SNF). The 125 
cytopathologist has the option of adding a descriptive comment to this DC (as to all other DCs), 126 
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which may be useful to better predict the histological diagnosis of the lesion in question. This is 127 
particularly important after the reclassification of the non-invasive encapsulated FV-PTC as 128 
NIFTP. In our institution, in case of cytological features suggestive of NIFTP, the following 129 
comments are added to the diagnosis as a note: ͞The presence of rare atypical nuclear features 130 
in this follicular-patterned lesion suggests the possibility of a FV-PTC or NIFTP͟. 131 
The advent of NIFTP made necessary also an adjustment in the FN/SFN DC. In the 132 
updated version, cases with slight nuclear atypia are also included in this DC, and they can 133 
correspond to NIFTPs found on histology. Conversely, because the M DC must retain a high 134 
positive predictive value for cancer, it should comprise only cases with multiple typical nuclear 135 
features of PTC; these can include nuclear enlargement, nuclear membrane irregularities, 136 
frequent nuclear grooves, abnormal chromatin clearing and/or nuclear inclusions. Cases of 137 
NIFTP typically have less well-developed nuclear atypia and almost never have nuclear 138 
inclusions.  Psammoma bodies are rare in FNAC specimens but are very helpful when present as 139 
they are not found in NIFTP. Papillary arrangement also, by definition, is absent in NIFTP. Given 140 
that papillary architecture excludes NIFTP, it is important to be aware that nodules can still be 141 
classified in the M DC as a cytological diagnosis of PTC even if they do not display abundant 142 
papillary structures, because the latter are not always present and thus not necessary for 143 
diagnosis; in such cases, the diagnosis is usually supported by the presence of abundant and 144 
convincing nuclear atypia. 145 
 146 
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FAQ 2: What are the reasons for a ND/UNS classification?  Does it depend primarily on the 147 
nodule, the FNA operator or the cytopathologist? And what are the implications? 148 
A ND/UNS classification normally does not depend on the cytopathologist, because she or he 149 
needs to follow specific predefined criteria to evaluate the quality and adequacy of the sample 150 
(Cf. FAQ 5-7 for more details). In that sense, it is unlikely that a more ͞defensive͟ 151 
cytopathologist will triage borderline and/or difficult cases into the ND/UNS DC (but rather into 152 
the AUF/FLUS DC; Cf. FAQ 7-9). 153 
There are some rare types of nodules that can be associated with a high risk of ND/UNS results, 154 
such as solitary fibrous tumors, schwannomas, fibrotic Hashimoto’s disease or Riedel’s 155 
thyroiditis. In these cases, the target lesion contains very few, if any, follicular cells.  156 
In the majority of cases then, the reason for ND/UNS DC rests with the FNA operator, and it has 157 
to do with poor technique in sampling, slide preparation or fixation (Cf. FAQ 5 and 7 for more 158 
details on specific quality issues). According to the Bethesda guidelines, no more than 10% of 159 
specimens should be classified as ND/UNS. However, the percentage of nodules classified as 160 
ND/UNS in real life varies widely in the literature, ranging from 1-2% to as high as 45-50% (17). 161 
The higher end of this spectrum is way beyond the acceptable 10% threshold and thus clearly 162 
reflects poor practice. At this higher end, the ROM could also be significantly impacted, 163 
especially if there is a systematic bias, associated with the underlying reason for the high 164 
percentage of ND/UNS specimens, notably marginal specimens due to poor sampling or 165 
preparation techniques. Therefore, in order to keep the rate of ND/UNS reports as low as 166 
possible, or at least within acceptable limits (10%), specimen quality is of paramount 167 
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importance. This is why it is imperative that non-cytopathologist operators who perform 168 
thyroid FNA (most commonly endocrinologists or radiologists) receive dedicated training on 169 
quality issues related to FNA technique and sample preparation (18). Those who do not meet 170 
the 10% benchmark should be made aware (e.g., by their cytopathologist, or by their clinical 171 
supervisor if still in training) and further structured training to reach this goal should be 172 
expected. 173 
Poor specimen quality is a main cause of false-negative diagnoses; this can occur when the 174 
material is either not representative or so scant or poorly preserved that neoplastic cells cannot 175 
be identified (18). In addition, poor specimen quality is also implicated in false-positive 176 
diagnoses, when the cytopathologist attempts to force a diagnosis in cases with marginal 177 
material (18). Thus, high rates of ND/UNS samples cause increased cost and morbidity 178 
associated not only with repeat testing but also with unnecessary surgery; indeed, a substantial 179 
number of patients with ND/UNS results, especially after repeat FNA, will be addressed for 180 
surgery (Cf. FAQ 3), and it is well-known that after thyroid surgery about 2% of patients suffer 181 
from permanent laryngeal nerve damage and about 2% suffer from post-operative 182 
hypoparathyroidism. 183 
 184 
FAQ 3: When a nodule yields a ND/UNS result, is it more or less likely to be malignant? 185 
The malignancy risk associated with a non-diagnostic category was not clearly stated in 186 
the original TBSRTC publication (7). According to a large meta-analysis, the malignancy risk of 187 
this category, calculated among resected cases, was 9-32%, which is higher than that of a 188 
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benign diagnosis (9, 12). However, resected cases are a selected group of the total population 189 
of the ND/UNS nodules, often operated because of worrisome US features; a reasonable 190 
extrapolation of the overall malignancy risk in this category is 5-10%, as stated in the new 191 
version of the TBSRTC (17). This is the reason why close follow up or even surgery is suggested 192 
for the 30% of all ND/UNS cases that are re-aspirated and that yield a second ND/UNS result, 193 
associated or not with suspicious US features. In case of one or more ND/UNS FNAC results, one 194 
can consider performing the FNA under US guidance followed by rapid on-site evaluation 195 
(ROSE); another option is core biopsy, as recommended by other reporting systems for such 196 
non-diagnostic cases (19, 20). 197 
 198 
FAQ 4: When a nodule yields a ND/UNS result, can the biopsy be repeated rapidly, or does a 199 
3-6 month waiting period apply as for AUS/FLUS results? 200 
For the cytopathologist, the 3-6 month waiting period before repeating the FNA after a 201 
ND/UNS result is justified by the presence of reparative and regenerative changes, which, if 202 
sampled during the second FNA, can lead to a false-positive cytological diagnosis. On the other 203 
hand, from the clinician’s perspective, one can just repeat the biopsy without delay, and 204 
perform a delayed third biopsy in case of a AUS/FLUS result on the second FNAC. This strategy 205 
will allow to reassure many patients immediately and to avoid 3 months of possible worry or 206 
even distress. Two studies have actually suggested that a 3 month waiting period is not 207 
necessary for initially non-diagnostic aspirates (21, 22); the same might be true for initially 208 
atypical aspirates (AUS/FLUS), but this particular question has not yet been addressed with 209 
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sufficiently high numbers of cases (21). The ATA 2015 guidelines state that a waiting period is 210 
probably not necessary (12).  211 
 212 
FAQ 5: When a nodule aspirated under US guidance yields a few isolated normal (non-213 
atypical) follicular cells, why it is classified as ND/UNS and not as benign? 214 
The widespread use of FNA coupled with US allows the operator to be certain that the 215 
aspirated material indeed comes from the intended target lesion. However, even if the FNA 216 
practitioner is sure about which lesion has been sampled, this is not sufficient for the 217 
cytopathologist to establish a diagnosis of benignity based only on a few normal, non-atypical 218 
follicular cells. One of the major achievements of TBSRTC was that it addressed not only DCs 219 
but also quality issues, procedures, and standardization of reporting terminology. One of these 220 
topics concerns the specimen’s adequacy. The assessment of pre-analytical issues, such as 221 
specimen adequacy, according to specific criteria, is the basis to ensure a high-quality result 222 
with a low false-negative rate, as well as to ensure that any downstream molecular test is 223 
applied on the appropriate target cell population.  224 
In general, there is a minimum requirement of 6 groups of follicular cells, which should 225 
contain at least 10 thyrocytes each. These follicular cell groups should be well-preserved, well-226 
stained and not covered by blood cells that obscure their features (7). Of note, the 227 
cytopathologist cannot combine cells present in two or more ND/UNS results to try to meet the 228 
above criteria. The problem with isolated thyrocytes, even when they are present in a well-229 
prepared and well-stained specimen coming from a nodule properly sampled under US 230 
12 
 
guidance, is that they do not permit the cytopathologist to appreciate the architectural 231 
arrangement of the underlying lesion. It is thus impossible to establish whether the lesion is 232 
macrofollicular or microfollicular. 233 
The clinician should also be aware of some exceptions to the above criteria. Some FNA 234 
aspirates may be diagnosed as benign even without the presence of 6 groups of follicular cells 235 
with at least 10 thyrocytes each. This concerns aspirates from: (1) colloid nodules, which are 236 
extremely dilated follicles filled with colloid, producing a specimen composed entirely of colloid 237 
material; (2) nodules with inflammation (typically in the context of autoimmune, infectious, or 238 
chronic inflammatory thyroid disease), where in the presence of abundant colloid and 239 
abundant inflammatory cells, a few follicular cells are sufficient to diagnose the nodule as 240 
benign; and (3) cystic nodules, where the typical cystic content (macrophages, 241 
hemosiderophages, red blood cells, fibrin and colloid) should be classified in the ND/UNS DC; 242 
nevertheless, in such cases, the clinician can treat the nodule as benign based on a 243 
clinicopathological correlation with non-suspicious US imaging compatible with a pure cyst 244 
(often aspirated for volume reduction and/or symptomatic relief of compressive symptoms) 245 
(17). 246 
Lastly, FNAC of developmental thyroid cysts can yield only cystic fluid, macrophages and 247 
rare epithelial cells (mostly squamous) with a benign appearance. In such cases, a diagnosis of 248 
benignity consistent with a developmental cyst such as a thyroglossal duct cyst can be rendered 249 
cytologically; a clinicopathological correlation should be encouraged. 250 
 251 
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FAQ 6: Why is there still a residual risk of malignancy associated with a benign classification? 252 
Indeed, even if the FNA is performed under US guidance, and thus the clinician is sure 253 
about having sampled the correct target nodule, the ROM is not equal to zero. The reported 254 
ROM range taken from TBSRTC is 1-3%, while risk estimates reported in the literature vary 255 
between 1-10% and can be as high as 22% in nodules larger than 3 cm (23). One possible 256 
explanation concerns cases with suboptimal preparation and staining that are incorrectly 257 
diagnosed as benign even though they should have been classified as ND/UNS. In this respect, it 258 
is also important to note that although 6 clusters composed of 10 thyrocytes each qualify a 259 
specimen as adequate for diagnosis, more abundant material generally facilitates a more 260 
secure diagnosis and thereby contributes to minimize the ROM in this category. When samples 261 
are properly prepared and stained, discrepancies arise mostly due to errors in the 262 
interpretation of the cytological features, especially in the category of FV-PTC, where nuclear 263 
changes are subtle; if such features are not properly recognized, then a false-negative diagnosis 264 
may be rendered. Finally, a rare caveat is the macrofollicular variant of FTC (24, 25); these 265 
tumors show capsular and/or vascular invasion, yet the FNA yields primarily macrofollicles, and 266 
thus the lesion is classed as ND/UNS and not as FN/SFN, which is the case with the common FTC 267 
variant, where microfollicles are predominant. These caveats justify the management 268 
recommendation to perform at least one US follow-up examination of patients with a benign 269 
FNAC diagnosis. 270 
 271 
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FAQ 7: Are there underlying clinical conditions that favor classification of nodules as 272 
AUS/FLUS? If so, might informing the cytopathologist change the diagnosis? 273 
Some lesions are classified under the AUS/FLUS category because the specimen is 274 
qualitatively compromised. A badly smeared, fixed or stained preparation is thus classified as 275 
AUS/FLUS because of technical reasons that do not depend on the nature of the lesion itself or 276 
any associated clinical conditions. For example, FNA on patients treated with anticoagulants 277 
can yield bloody aspirates. In this case, smears can be covered by blood that obscures the 278 
characteristics of the follicular cells and prevents their correct interpretation. In such a 279 
scenario, awareness of the anticoagulation treatment will not change the classification, as the 280 
issue is technical. In contrast, when the sample shows cytological atypia, it is of paramount 281 
importance that the cytopathologist has been informed of the patient’s clinical conditions in 282 
order to correlate them correctly with the cytological findings. For example, antithyroid 283 
medications (thionamides) could be responsible for the presence of atypical thyrocytes with a 284 
so-called ͞flaming cytoplasm͟; if such treatment is not disclosed by the clinician, the cytology 285 
might be inappropriately reported as atypical (AUS/FLUS or even FN/SFN).  286 
Other important information to disclose to the cytopathologist is prior external beam 287 
radiation therapy or radioactive iodine therapy. Both can result in cellular enlargement and 288 
nuclear atypia that can lead to classification in the AUS/FLUS or SM DC (26).   289 
Clinically evident cases of thyroiditis are occasionally subjected to FNA for diagnostic or 290 
research purposes. In cases of florid or sclerosing thyroiditis without a clearly identified nodule 291 
on US, slightly atypical nuclei (clearing of the chromatin, increased nuclear size, grooves) in an 292 
15 
 
otherwise benign-appearing aspirate can be correctly interpreted as related to thyroiditis, thus 293 
classified as benign and avoiding repeat FNA or further interventions. 294 
Because it is widely fibrotic, sclerosing thyroiditis may yield too few cells upon FNA; in 295 
such cases, the scanty cellularity can be considered worrisome in case of presence of some 296 
atypical cells suggesting PTC. Indeed, slightly atypical nuclei with the same characteristics as in 297 
sclerosing thyroiditis can be observed in cases of PTC with desmoid-type fibromatosis, a rare 298 
PTC variant that presents with a well-defined nodule containing a hyperechoic zone on US 299 
consistent with sclerosis/fibrosis. Thus, the clinical context, including the US characteristics of 300 
the lesion, is critical to guide the interpretation of the cytological findings (27). 301 
These examples illustrate how the communication by the clinician of relevant clinical 302 
information to the cytopathologist is essential in order to correctly interpret atypical cytological 303 
findings. The clinicopathological correlation can facilitate a correct interpretation of the 304 
observed atypia and thus guide the further clinical management of the patient. An exhaustive, 305 
yet user-friendly requisition form can greatly help to ensure that the clinician does not omit any 306 
important clinical information that the cytopathologist could need (Table 1). 307 
 308 
FAQ 8: For a AUS/FLUS nodule, is it clinically relevant to explain the specific subcategory, the 309 
reason for the classification and the type of cancer possibly associated? 310 
The AUS/FLUS DC comprises several scenarios with different associated ROM (28).  In 311 
the new version of TBSRTC the generic term AUS/FLUS is maintained, but it is suggested to add 312 
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a note describing the pattern of the lesion among the most common patterns that have been 313 
identified in a large literature review (13). These patterns include nuclear atypia (i.e., the 314 
presence of features associated with PTC); architectural atypia [(i.e., the presence of 315 
microfollicles suggesting follicular adenoma vs. follicular thyroid carcinoma (FTC)]; oncocytic 316 
features (i.e., the presence of Hürthle cells with eosinophilic granular cytoplasm and prominent 317 
nucleoli); and ͞not otherwise specified͟ (NOS) in case the atypia observed cannot be classified 318 
in any of the aforementioned patterns. Among these four patterns, the malignancy risk 319 
decreases progressively from nuclear atypia (highest) to NOS (lowest). Knowledge of the 320 
precise ROM associated with the specific qualifier of a AUS/FLUS lesion can be very useful for 321 
the clinician who is charged to discuss repetition of the FNA with the patient and/or to propose 322 
alternatives. One such alternative can be molecular genetic testing, as also suggested by the 323 
ATA 2015 guidelines and the ETA 2017 guidelines (Figure 1) (12, 29). For example, without 324 
knowing the qualifier of the AUS/FLUS diagnosis, one might propose a molecular test for a 325 
AUS/FLUS case diagnosed as such because of quality issues (Figure 2), which would be 326 
inappropriate. Moreover, in an effort to propose a personalized cytology, and in view of the 327 
paucity of material frequently observed in AUS/FLUS cases, the cytopathologist together with 328 
the clinician (as is the practice in our center) can also select the most appropriate molecular 329 
markers, such as mutational analysis of the BRAF V600E point mutation and PET/PTC 330 
rearrangements in cases with nuclear atypia, or the BRAF K601E, RAS point mutations and 331 
PAX8/PPAR gamma rearrangement in cases with architectural atypia. The 2017 ETA guidelines 332 
provide a detailed discussion of the potential and limitations of molecular genetic testing (29). 333 
 334 
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FAQ 9: When will a predominantly microfollicular lesion be classified as AUS/FLUS and when 335 
as FN/SFN? 336 
Predominance of microfollicles can be observed in case of a paucicellular aspirate or in 337 
case of a highly cellular aspirate. In the first situation, the appropriate diagnosis would be 338 
͞AUS/FLUS, architectural atypia͟. The cytopathologist is reluctant to induce a diagnostic 339 
lobectomy in these cases and prefers to have the patient undergo a repeat FNA in the hope of 340 
obtaining more material that will allow to reach a more accurate diagnosis. In the second 341 
situation, a highly cellular aspirate with predominance of microfollicles, the appropriate 342 
diagnosis would be FN/SFN. What is still not clearly defined is the minimum amount of 343 
microfollicles necessary for a FN/SFN diagnosis. Also, it is important to remember that slight 344 
nuclear atypia is now included in the FN/SFN DC; in fact, in presence of a microfollicular pattern 345 
with nuclear atypia, it is also possible that the lesion is a NIFTP (which can only be diagnosed on 346 
surgical pathology), as already mentioned in FAQ1. 347 
 348 
FAQ 10: Can a FN/SFN nodule be a PTC? 349 
In the FN/SFN DC (10-40% ROM) are usually classified lesions that contain a 350 
predominant or exclusive population of microfollicles. When such lesions are subjected to 351 
diagnostic surgery (normally lobectomy), the main histological correlates of these aspirates are 352 
benign proliferations, namely hyperplasic nodules/follicular adenomas, and in a lower 353 
proportion malignant lesions, namely FTC (9, 13). Some malignant cases corresponded in the 354 
past to FV-PTC. This variant is characterized by a microfollicular structure and subtle nuclear 355 
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changes in the sense of PTC, namely nuclear clearing and grooves, with few or no nuclear 356 
inclusions; these subtle nuclear changes can often pass unnoticed, leading to a FN/SFN 357 
diagnosis of these lesions (30, 31).  With the modification in the nomenclature and the 358 
introduction of NIFTP as a lesion of low malignant potential, fewer PTC cases will be found in 359 
the FN/SFN diagnostic category, thus reducing the lower end of the ROM of the FN/SFN DC (32, 360 
33). Notwithstanding this improvement in the diagnostic classification, some invasive FV-PTC 361 
still will be diagnosed in the FN/SFN DC, because the presence or absence of capsular or 362 
vascular invasion cannot be assessed on cytological material. 363 
 364 
FAQ 11: Can a SM nodule be other than PTC? 365 
In the majority of cases, a SM nodule turns out to be PTC upon histological examination. 366 
In this DC are classified cases that contain atypical nuclear features suspicious for PTC (either 367 
the classical or the follicular variant), but that are not sufficient for a conclusive diagnosis of 368 
PTC. However, the degree of suspicion is higher than that of the cytological atypia component 369 
in the AUS/FLUS DC (Cf. FAQ 8); as a consequence, surgery is indicated (Cf. FAQ 16). Nuclear 370 
atypia, in particular nuclear pseudoinclusions, are not seen exclusively in PTC, but sometimes 371 
also in medullary thyroid carcinoma (MTC), along with salt-and-pepper chromatin, granular 372 
cytoplasm and absence of colloid. MTC is actually the second most frequent histological 373 
diagnosis in case of SM cytological findings (when all the above characteristic of MTC are not 374 
present). Other types of tumors that can be suspected on cytology and confirmed on histology 375 
include trabecular adenoma, poorly differentiated thyroid carcinoma (PDTC), anaplastic thyroid 376 
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carcinoma (ATC), lymphoma, sarcoma and metastases of extra-thyroidal primary tumors. A 377 
good percentage of NIFTP also fall in this DC, which is why the ROM of an SM classification 378 
decreases substantially when NIFTP is not considered a cancerous lesion (7, 13, 32, 33). 379 
 380 
FAQ 12: What is the major cytological difference between the SM and M DCs? 381 
The main difference between the SM and M DCs is that in the former the cytological 382 
criteria for malignancy are not completely met, yet the level of suspicion is high. Histologically 383 
proven FTCs are typically not found in the SM or M DCs. This is because the criteria for 384 
malignancy in follicular lesions are histological, requiring examination of the tumor’s capsule 385 
and of the vessels in the capsule; therefore, these tumors cannot be diagnosed purely on 386 
cytological grounds. Except for FTC, which, as mentioned, is typically not classified in the SM 387 
DC, all other types of thyroid carcinoma may be classified in this DC based on a preoperative 388 
FNAC if the cytological criteria present are not sufficient to warrant a confident diagnosis of 389 
malignancy. Among epithelial tumors, MTC, PDTC or ATC can be classified in the SM DC, but the 390 
most frequent type is by far PTC. For PTC, SM designation is usually reached in cases with 391 
limited material and/or when some of the following features are missing: pseudoinclusions, 392 
psammoma bodies, papillary structures, nuclear membrane irregularity and nuclear grooves. In 393 
such a scenario, when a microfollicular pattern is present, there is a highly probability that the 394 
lesion is FV-PTC, but the cytopathologist cannot be totally certain. 395 
 396 
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FAQ 13: In which TBSRTC DC would a NIFTP be classified? 397 
Even though a diagnosis of NIFTP can only be made on surgical pathology, it is 398 
interesting to consider the spectrum of possible presurgical cytological diagnoses associated 399 
with these lesions. It has been shown that histologically proven NIFTP had been classified 400 
preoperatively in mainly three DCs: AUS/FLUS, FN/SFN and SM, with frequencies that were 401 
variable among different centers (32, 33). Like for any other lesion, a lesion later shown to be a 402 
NIFTP may be classified preoperatively in the ND/UNS category, when the material is 403 
insufficient. Beyond that, the precise DC into which a specific lesion later proven to be a NIFTP 404 
may be classified on presurgical cytology depends on various factors, including the degree of 405 
nuclear atypia, the extent of microfollicular architecture, the quality of the specimen and, last 406 
but not least, the experience of the cytopathologist. A pathology-proven NIFTP should normally 407 
not have been classified as a benign lesion on cytology, because the presence of atypia and/or 408 
microfollicles warrants classification in a DC with higher ROM. It should also typically not have 409 
been classified as a malignant lesion, because papillary structures are absent, the degree of 410 
nuclear atypia is milder and the presence or absence of capsular and vascular invasion cannot 411 
be assessed on cytological material. Nevertheless, the risk of the M DC also decreased slightly 412 
after the introduction of NIFTP (from 97-99% to 94-96%) (15), indicating that a small number of 413 
nodules ultimately shown to be NIFTP do end up in the M DC based on FNAC. 414 
From a pre-surgical point of view, given that NIFTP is considered a lesion with a low 415 
malignant potential, the most important consequence of renaming non-invasive encapsulated 416 
FV-PTC into NIFTP is that it resulted in a decrease of the ROM of the aforementioned DCs 417 
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(AUS/FLUS, FN/SFN and SM). Among multicentric studies, the corresponding reduction of the 418 
ROM varied greatly (33). For this reason, the new Bethesda version provides a range for the 419 
ROM taking into account the new nomenclature (Table 2). Because the introduction of NIFTP is 420 
quite recent and not yet ubiquitously accepted, the new Bethesda version cites two ROM 421 
ranges for each DC, a higher one for when NIFTP is considered a cancerous lesion (not shown) 422 
and a lower one when it is considered a lesion with low malignant potential (Table 2). 423 
Admittedly, if one subscribes to the NIFTP concept, then only the respective lower ROM ranges 424 
are relevant. 425 
 426 
FAQ 14: Which signs raise suspicion of MTC, and in which DC is an MTC likely to be classified? 427 
Depending on the suspicious features present in each particular case, MTC is usually 428 
diagnosed in the SM or M DC. The most striking cytological features suggestive of MTC are the 429 
absence of colloid and the presence of a salt-and-pepper chromatin and of a granular 430 
eosinophilic cytoplasm. Presence of nuclear pseudoinclusions does not exclude a diagnosis of 431 
MTC, as MTC can indeed also present with abundant nuclear pseudoinclusions (Figure 3). MTC 432 
is in fact considered a great mimicker, as it can assume the most disparate cytological features, 433 
such as spindle cells or oncocytic cells; this can occasionally lead to classification in the SM DC 434 
as suspicious for PTC, or in the M DC as PTC or even as sarcoma or metastatic disease. In cases 435 
where MTC is suspected based on clinical features or based on cytological findings of ROSE at 436 
the time of FNA sampling, then collection of material for cell block can allow for 437 
immunocytochemical staining for calcitonin, confirming the diagnosis if cytomorphology alone 438 
22 
 
does not allow for a definitive diagnosis. Measurement of calcitonin (which should be high in 439 
MTC) and possibly also thyroglobulin (which should be low or undetectable) in the needle 440 
washout is also very helpful in such cases. 441 
 442 
FAQ 15: When a suspicious lymph node is aspirated in the context of a co-existing thyroid 443 
nodule, how relevant is it for the cytopathologist that the nodule also be aspirated? 444 
Strictly speaking, it is not necessary, because in general the cytological diagnosis of the 445 
lymph node is independent from that of the thyroid nodule. In rare cases when there are some 446 
atypical cells in the FNAC of the lymph node that are suspicious for PTC, an ancillary study, such 447 
as immunostaining for thyroglobulin or TTF-1, if positive, can confirm the presence of 448 
metastatic PTC. Finally, measuring thyroglobulin in the needle washout of the FNA sample can 449 
confirm metastatic disease when there is paucity or lack of tumor cells in the specimen and an 450 
immunohistochemical staining cannot be performed. Because this is obviously not known 451 
beforehand, routine measurement of thyroglobulin in the aspirate (or at least conservation of 452 
an appropriate sample for later measurement if necessary) should be strongly considered. 453 
As a general point, if a thyroid nodule is suspicious and warrants FNA, it is overall logical 454 
to biopsy it at the same time as the suspicious lymph node, because otherwise, if the lymph 455 
node FNA is negative, then the question about the nature of the thyroid nodule would remain 456 
and the patient would need to return for FNA of the thyroid nodule. On the other hand, if a 457 
lymph node is highly suspicious on US and the thyroid contains multiple nodules of which none 458 
is highly suspicious, it may be reasonable to perform FNA only on the lymph node, which will be 459 
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sufficient to guide further management if the result confirms metastasis of thyroid carcinoma, 460 
given that total thyroidectomy with compartment-based lymph node dissection is indicated in 461 
such cases. 462 
 463 
FAQ 16: In which cases is a frozen section useful to guide surgical management? 464 
Given the high risk of malignancy in SM cases, surgery is normally warranted with a 465 
diagnostic and therapeutic intent. If there is a dilemma between total thyroidectomy and initial 466 
diagnostic lobectomy (if indicated with completion surgery in case of malignancy confirmed on 467 
histology), then preoperative confirmation of malignancy may also be achieved by molecular 468 
genetic testing, in particular by detecting alterations associated with PTC with very high positive 469 
predictive value, such as a BRAF V600E mutation or a RET/PTC rearrangement. Alternatively, or 470 
for cases where molecular genetic testing results do not confirm malignancy, a frozen section 471 
analysis during diagnostic lobectomy may provide perioperative confirmation of malignancy in 472 
some cases. This depends largely upon the recognition of typical features of classical PTC, 473 
notably papillary structures and severe nuclear atypia. There are two main limitations: The first 474 
is that the quality of the specimen obtained during a frozen section is lower than that obtained 475 
during routine histopathological examination. Thus, among lesions classified in the SM DC that 476 
are finally proven to be classical PTC cases on histology, not all could be confirmed as such on 477 
frozen section analysis. The second limitation is that the single frozen section obtained may not 478 
be representative of the lesion as a whole. Therefore, follicular patterned lesions are 479 
inappropriate candidates for frozen section analysis, because even in cases of invasive FV-PTC 480 
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or FTC, the likelihood of detecting capsular or vascular invasion in a single frozen section is 481 
exceedingly low. 482 
 483 
CONCLUSIONS 484 
Although there are no formal studies on this topic, close communication between the 485 
cytopathologist and the clinician can help to optimize the diagnostic accuracy of thyroid FNAC. 486 
In our experience, good ways to interact constructively and to develop a deeper mutual 487 
understanding of the intricacies and challenges of each other’s discipline include joint US-FNA 488 
clinics with ROSE for selected nodules; multidisciplinary tumor boards; clinicopathological 489 
discussions of cases in the cytopathology unit while studying the slides of typical and atypical 490 
cases under a multi-observer microscope; as well as dedicated combined workshops and 491 
practical courses. We hope that the present overview will serve as an additional resource to 492 
this end. 493 
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Table 1. Outline of the thyroid FNA requisition form used in our center to transmit clinical 
information to the cytopathologist. 
Patient’s name 
Date of birth 
Unique identifier in the hospital 
 
Nodule’s dimensions and volume 
 
….. length (cm)   x  …..  width (cm)   x  ..… thickness (cm) 
….. volume (ml) 
Nodule’s localization right lobe    /    left lobe     /     isthmus 
superior      /    middle       /     inferior 
Nodule’s US characteristics microcalcifications:                Y / N                                               
central vascularization:         Y / N                                               
irregular margins:                  Y / N                                               
hypoechogenicity:                 Y / N 
irregular or incomplete halo:  Y / N 
taller than wide:                     Y / N 
cystic component:                  Y (….…%) / N 
Suspicious lymph node(s) Y / N                                                               
Previous FNA Y / N 
If yes: Date:………………    Result:……………… 
Thyroid autoimmunity none    /   Hashimoto’s    /    Graves’ 
TSH level ….… mIU/L 
 
Thyroid medications none / antithyroid drugs / levothyroxine 
 
Previous external beam radiotherapy Y / N 
Previous radioiodine treatment Y / N 
Family history of thyroid carcinoma Y / N 
Personal history of thyroid carcinoma Y / N  
Non-thyroidal primary malignancy Y (specify……………….)/ N                                                            
 
  
Table 2. The updated risk of malignancy ranges and management recommendations proposed 
by the new version of TBSRTC. 
Bethesda DC* % ROM* 
(NIFTP ≠ cancer) 
Management recommendation 
ND/UNS Non diagnostic, unsatisfactory 
 
5 - 10 Repeat FNA with ultrasound 
guidance 
B Benign 
 
0 - 3 Clinical and ultrasonographic 
follow-up 
AUS/FLUS Atypia of undetermined significance  
or follicular lesion of undetermined 
significance 
 
6 - 18 Repeat FNA, molecular testing 
or lobectomy 
FN/SFN Follicular neoplasm  
or suspicious for a follicular 
neoplasm 
 
10 - 40 Molecular testing, lobectomy 
SM Suspicious for malignancy 
 
45 - 60 Near-total thyroidectomy or 
lobectomy 
M Malignant 
 
94 - 96 Near-total thyroidectomy or 
lobectomy 
*DC: diagnostic category; ROM: risk of malignancy. Adapted from Cibas ES, Ali SZ 2017 The 
2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 27:1341-1346. 
FIGURE LEGENDS 
Figure 1: A classical variant of PTC initially classified as AUS/FLUS and then diagnosed as M 
(PTC) via molecular genetic testing. A 25-year-old female with a 2.3 cm nodule in the left 
thyroid lobe underwent US-guided FNAC. A. Few groups of thyrocytes were present on the slide 
(liquid based cytology, Papanicolaou staining, 600x) and presented focal atypia, namely rare 
grooves (arrows). The result rendered was AUS/FLUS. According to TBSRTC, she should undergo 
repeat FNAC, but she refused. In the context of cellular atypia without architectural atypia in a 
specimen that was not highly cellular, targeted molecular genetic testing was performed for 
BRAF hotspot mutations and RET/PTC translocations. B. Pyrosequencing demonstrated a 
c.1799T>A (p.V600E) BRAF mutation, diagnostic for PTC. The patient underwent surgery and 
histopathology confirmed the diagnosis of a PTC, classical variant. 
Figure 2: A case of NIFTP classified in the Bethesda AUS/FLUS and SM DCs. A 52-year-old 
female with a 1.8 cm nodule located in the isthmus underwent US-guided FNAC. A. The 
specimen was highly cellular but badly fixed and stained. Thyrocytes were enlarged, stained 
reddish and chromatin details were not well visible. Some probable grooves (arrows) were 
identified and a possible nuclear pseudoinclusion (arrowhead) was also suspected (smear, 
Papanicolaou staining, 400x). The poor quality of the specimen did not allow establishing a 
definitive cytological diagnosis, and the case was rendered as AUS/FLUS. B. The patient 
underwent a repeat US-guided FNAC 6 months later with a SM diagnosis (suspicious for PTC): 
the smears were hypercellular with abundant microfollicular structures, abundant grooves 
(arrows) and what were thought to be nuclear pseudoinclusions (arrowhead). The patient 
underwent diagnostic lobectomy (without frozen section) (smear, Papanicolaou staining, 200x). 
C. The histological specimen was consistent with NIFTP; in contrast to the initial cytological 
suspicion (A), no nuclear pseudoinclusions were identified, only chromatin clearing was present 
(hematoxylin and eosin staining, 200x). 
Figure 3: A case of MTC correctly classified in the M DC and confirmed as a neuroendocrine 
tumor using immunocytochemistry. A. An aspirate from a 75-year-old man showing 
plasmocytoid, polygonal cells and nuclei with granular chromatin. Some nuclear 
pseudoinclusions were present (arrows); pseudoinclusions are not exclusively present in PTC, 
but also in MTC (Papanicolaou staining, 400x). B. Based on the immunocytochemical 
confirmation of the neuroendocrine nature of the lesion (Chromogranin staining) the final 
diagnosis was: positive for malignant cells consistent with MTC (Papanicolaou staining, 600x). 
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